The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

The tumor necrosis factor (TNF)-α inhibitor infliximab is used to treat a variety of immune-mediated inflammatory diseases, including IBD (CD and UC) and RA, in which the cytokine TNF plays a central ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...